EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zai Lab's Enterprise Value is $657.7 Mil.
Zai Lab's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-374.1 Mil. Therefore, Zai Lab's EV-to-EBIT for today is -1.76.
The historical rank and industry rank for Zai Lab's EV-to-EBIT or its related term are showing as below:
ZLAB'
s EV-to-EBIT Range Over the Past 10 Years
Min: -55.35 Med: -12.92 Max: -1.53
Current: -1.76
During the past 9 years, the highest EV-to-EBIT of Zai Lab was -1.53. The lowest was -55.35. And the median was -12.92.
ZLAB's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs ZLAB: -1.76
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Zai Lab's Enterprise Value for the quarter that ended in Dec. 2023 was $1,865.8 Mil.
Zai Lab's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-374.1 Mil. Zai Lab's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -20.05%.
Zai Lab EV-to-EBIT Historical Data
The historical data trend for Zai Lab's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zai Lab's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, Zai Lab's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zai Lab's EV-to-EBIT falls into.
Zai Lab's current Enterprise Value is $657.7 Mil.
Zai Lab's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-374.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (NAS:ZLAB) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zai Lab's Enterprise Value for the quarter that ended in Dec. 2023 was $1,865.8 Mil.
Zai Lab's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-374.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Zai Lab's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZLAB has been successfully added to your 